These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

672 related articles for article (PubMed ID: 15355920)

  • 1. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
    Ichikawa W; Takahashi T; Suto K; Sasaki Y; Hirayama R
    Clin Cancer Res; 2006 Jul; 12(13):3928-34. PubMed ID: 16818689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
    Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
    Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    Iacopetta B; Grieu F; Joseph D; Elsaleh H
    Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.
    Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
    Merkelbach-Bruse S; Hans V; Mathiak M; Sanguedolce R; Alessandro R; Rüschoff J; Büttner R; Houshdaran F; Gullotti L
    Oncol Rep; 2004 Apr; 11(4):839-43. PubMed ID: 15010882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
    Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
    Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thymidylate synthase gene promoter polymorphism in patients with advanced head and neck cancer treated by radio- and 5-fluorouracil chemotherapy].
    Kiss-László Z; Nagy B; Thurzó L; Szabó J
    Magy Onkol; 2006; 50(1):33-7. PubMed ID: 16617381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer.
    Ishida Y; Kawakami K; Tanaka Y; Kanehira E; Omura K; Watanabe G
    Anticancer Res; 2002; 22(5):2805-9. PubMed ID: 12530000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer.
    Calascibetta A; Cabibi D; Martorana A; Sanguedolce G; Rausa L; Feo S; Dardanoni G; Sanguedolce R
    Anticancer Res; 2004; 24(6):3875-80. PubMed ID: 15736425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
    Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
    Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of thymidylate synthase gene and chemosensitivity of 5-fluorouracil regimen in metastatic gastrointestinal cancer.
    Cui YH; Liu TS; Zhuang RY; Gao HJ; Li H
    J Dig Dis; 2009 May; 10(2):118-23. PubMed ID: 19426394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer.
    Chen J; Hunter DJ; Stampfer MJ; Kyte C; Chan W; Wetmur JG; Mosig R; Selhub J; Ma J
    Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):958-62. PubMed ID: 14578129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthetase allelic imbalance in clear cell renal carcinoma.
    Colavito D; Cartei G; Dal Bianco M; Stecca A; Zustovich F; Dalle Carbonare M; Ragazzi E; Farina M; Colombrino E; Leon A
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1195-200. PubMed ID: 19306093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between thymidylate synthase (TYMS) gene polymorphism and TYMS protein levels in patients with high-risk breast cancer.
    Fujishima M; Inui H; Hashimoto Y; Azumi T; Yamamoto N; Kato H; Hojo T; Yamato M; Matsunami N; Shiozaki H; Watatani M
    Anticancer Res; 2010 Oct; 30(10):4373-9. PubMed ID: 21036767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.